尿激酶型纤溶酶原激活系统与子宫内膜癌
摘要
尿激酶型纤溶酶原激活剂(uPA)系统通过水解纤溶酶原转变为纤溶酶降解细胞外基质,进而使肿瘤细胞不断浸润和扩散。该系统各成分的表达在子宫内膜癌组织中含量升高。本文就该系统的组成、结构、在肿瘤转移中的作用机制及其在子宫内膜癌中的研究进展作一综述,旨在为子宫内膜癌的诊断和治疗提供新的依据。
出处
《中国优生与遗传杂志》
2005年第9期116-118,共3页
Chinese Journal of Birth Health & Heredity
参考文献14
-
1Liu S,Bugge TH,Leppla SH.Targeting of tumor by cell surface urokinase plasminogen activator-dependent anthrax toxin[J].J Biol Chem,2001,276(21):17976-17984.
-
2Wojtukiewicz M,Sierko E,Zacharski LR,et al.Occurrence of components of fibriolytic pathways in situ in laryngeal cancer[J].Semin Thromb Hemost,2003,29(3):317-320.
-
3Ajani AE,Waksman R.Thrombolytic therapy in patients with submassive pulmonary embolism[J].N Engl J Med,2003,348(4):357-359.
-
4Podor TJ,Shaughnessy SG,Blackburn MN,et al.New insights int the size and stoichiometry of the plasminogen activator inhibitor type-1,vitronectin complex[J].J Biol Chem,2000,275(33):25402-25410.
-
5Czekay RP,Aertgeerts K,Curriden SA,et al.Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins[J].Cell Biol,2003,160(5):781-791.
-
6Blouse GE,Perron MJ,Thompson JH,et al.A concerted structural transition in the plasminogen activator inhibitor-1 michanism of inhibition[J].Biochemistry,2002,41(40):11997-12009.
-
7Taponeco F,Curcio C,Giuntini A,et al.Expression and prognostic significance of urokinase and plasminogen activator inhibitor type-1 in endometrial hyperplasia and cancer[J].J Exp Clin Cancer Res,2001,20(2):239-46.
-
8Memarzadeh S,Kozak KR,Chang L,et al.Urokinase plasminogen activator receptor:Prognostic biomarker for endometrial cancer[J].Proc Natl Acad Sci U S A,2002,99(16):10647-52.
-
9Tecimer C,Doering DL,Goldsmith LJ,et al.Clinical relevance of urokinase-type plasminogen activator,its receptor,and its inhibitor type 1 in endometrial cancer[J].Gynecol Oncol,2001,80(1):48-55.
-
10Foca C,Mosses EK,Quinn MA,Rice GE.Differential mRNA expression of urokinase-type plasminogen activator,plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas[J].Gynecol Oncol,2000,79(2):244-50.
-
1王丽华,肖伟,Richard B Moss,Yao-pi Hsu.支气管哮喘患者诱导痰尿激酶型纤溶酶原激活系统状态的研究[J].中华结核和呼吸杂志,2006,29(2):124-124.
-
2毛晓丽,朱艳.尿激酶型纤溶酶原激活剂(uPA)系统在子宫内膜癌中的研究进展[J].中国工程科学,2006,8(5):98-102. 被引量：2
-
3刘岩丽,谭文华,关咏梅.子宫内膜腺癌组织中尿激酶型纤溶酶原激活系统的表达及其临床意义[J].现代肿瘤医学,2009,17(11):2195-2197.
-
4王利娟,刘惠喜.尿激酶型纤溶酶原激活剂系统与妇科肿瘤[J].国外医学（妇幼保健分册）,2002,13(2):85-87. 被引量：2
-
5牛义凯,肖伟,朱媛媛.肺癌患者血浆尿激酶型纤溶酶原激活系统的研究[J].中国肺癌杂志,2006,9(4):369-372. 被引量：3
-
6王靖雯,沈朝妍,王伟,程建新.尿激酶型纤溶酶原激活系统与卵巢恶性肿瘤[J].国外医学（妇幼保健分册）,2005,16(6):431-434. 被引量：3
-
7吴桂珠,郑秀.肿瘤的浸润、转移与uPA系统的关系[J].海峡预防医学杂志,2005,11(2):25-27. 被引量：4
-
8洪龙年,张颖.浅谈尿激酶型纤溶酶原激活系统与卵巢恶性肿瘤的相关性[J].当代医药论丛,2014,12(7):171-173. 被引量：1
-
9凌丹,李力.纤溶酶原激活因子及抑制因子与卵巢癌浸润转移[J].国外医学（妇产科学分册）,2004,31(3):187-190.
-
10刘彬,皇甫超申,葛振英,康玉华.消化道恶性肿瘤患者血浆尿激酶型纤溶酶原激活系统测定的临床意义[J].陕西医学杂志,2003,32(12):1081-1082.
